Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is the purchase of Ordinary Shares by two individuals on October 5, 2006, under a Single Company ISA at a price of GBP14.49 per share:
- Mr J S Heslop: Acquired 4 shares.
- Mr A P Witty: Acquired 3 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding the notification of director transactions.
Investor Verification Points
- Verify the share price of GBP14.49 per Ordinary Share on October 5, 2006.
- Confirm the total shareholding positions of Mr J S Heslop and Mr A P Witty following these transactions.
- Review the company's broader financial reports (e.g., Form 20-F) for comprehensive performance metrics not included in this specific filing.